What Doctors Miss About Breast Cancer That Could Save Lives
In this monologue, the speaker argues that the prevailing breast‑cancer paradigm—systemic chemotherapy and standard surgery guided by population‑level NCCN guidelines—leads to overtreatment and harms patients. He claims that systemic chemo wipes out immune function, facilitating metastasis, and that surgery can further promote spread. The speaker promotes an integrative oncology approach: using a Sinatra DX molecular test to identify tumor‑specific targets, freezing the tumor early, and delivering chemotherapy at micro‑dose levels (around 10% of conventional doses). This low‑dose strategy is said to stimulate the patient’s innate immune system—particularly NK cells and dendritic cells—to recognize tumor antigens and neo‑antigens, generating a systemic anti‑tumor response that can protect both breasts. The central message is that targeted, immune‑focused care, rather than one‑size‑fits‑all protocols, could prevent recurrence and save lives.
